Cecilia Casetta

Clinical Lecturer

King’s College London
Country flagUnited Kingdom

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (6)

Objective Preclinical evidence suggests that modulating neural excitation through administration of diazepam, a positive allosteric modulator of GABAA receptors, can prevent the emergence of behavioral and neurobiological alterations relevant to psychosis in adulthood. Design and Participants Here, we examine this neurochemical mechanism in individuals at clinical high risk for psychosis in a randomized, double-blind, placebo-controlled crossover study. Twenty-four individuals (15 female and 9 male) aged 18-35 were scanned twice using proton magnetic resonance spectroscopy to measure anterior cingulate cortex Glx (glutamate and glutamine) levels, once after a single dose of diazepam (5 mg) and once after placebo. Results Mixed-effects model analyses revealed that diazepam reduced anterior cingulate cortex Glx levels compared to placebo (t(20.8) = −2.14, P = .04). The effect of diazepam on Glx levels was greater in older individuals at clinical high risk for psychosis (t(12) = −4.36, P = .001). Conclusion These findings suggest that pharmacological modulation of GABAA receptors can alter Glx changes in and support a novel therapeutic mechanism of benefit for individuals at clinical high risk of psychosis.

Year:

2026

Year:

2026

Background Clozapine remains underused despite its unparalleled efficacy in treatment-refractory schizophrenia. One of the reasons for its underuse is the fear of severe neutropenia and its consequences. Aims To scrutinise the association between severe neutropenia and clozapine in a cohort of patients clinically diagnosed with clozapine-induced severe neutropenia. Method We used data from the South London and Maudsley National Health Service Foundation Trust’s anonymised case register, known as the Clinical Record Interactive Search. We extracted details of cases where clozapine use was associated with two consecutive neutrophil counts below 1.5 × 10 9 /L. A panel of clinicians independently assessed each case. Agreement was reached on which cases clozapine was the likely or definite cause of the severe neutropenia, the risk to life and whether or not rechallenge with clozapine could be attempted. Results There were 96 cases where two consecutive neutrophil counts below 1.5 × 10 9 /L were registered. The panel judged that 9 (9.4%) were definitely caused by clozapine and a further 11 (11.5%) were probably caused by clozapine. Overall, 18 (18.8%) patients should be precluded from ever receiving clozapine again according to the panel (all from the 20 cases where clozapine was the definite or probable cause). Of the remaining 76 cases of severe neutropenia the cause could not be determined in 60 cases, but in 11 cases the cause was benign ethnic neutropenia, in 2 others the cause was cancer chemotherapy, in 2 it was infections and in 1 it was laboratory error. In almost 80% of cases, clozapine was not the clear cause of the neutropenia observed. Conclusions The large majority of severe neutropenia episodes mandating cessation of clozapine may not be caused by clozapine. Threshold-based monitoring systems cause unnecessary stopping of clozapine because they lack the necessary specificity for clozapine-related blood disorders.

Year:

2025

Preclinical evidence suggests that modulating neural excitation through diazepam administration, a positive allosteric modulator of GABA A receptors, can prevent the emergence of behavioural and neurobiological alterations relevant to psychosis in adulthood. Here, we examined this neurochemical mechanism in individuals at clinical high-risk for psychosis (CHRp) in a randomised, double-blind, placebo-controlled crossover study. Twenty-four individuals aged 18-35 were scanned twice using proton magnetic resonance spectroscopy ( 1 H-MRS) to measure anterior cingulate cortex (ACC) Glx (glutamate and glutamine) levels, once after a single dose of diazepam (5 mg), and once after placebo. Mixed-effects model analyses revealed that diazepam reduced ACC Glx levels compared to placebo (t(20.8) = −2.14, p = 0.04). The effect of diazepam on Glx levels was greater in older CHRp individuals (t(12) = −4.36, p = 0.001). These findings suggest that pharmacological modulation of GABA A receptors can alter glutamatergic changes in psychosis.

Year:

2024

Background Elevated hippocampal perfusion has been observed in people at clinical high-risk for psychosis (CHR-P). Preclinical evidence suggests that hippocampal hyperactivity is central to the pathophysiology of psychosis, and that prophylactic treatment with diazepam during adolescence can prevent the development of psychosis-relevant phenotypes. Here we examined whether diazepam normalises hippocampal perfusion in CHR-P individuals. Methods Using a randomised, double-blind, placebo-controlled, crossover design, 24 CHR-P individuals were assessed with MRI on two occasions, once following a single oral dose of diazepam (5 mg) and once following placebo. Regional cerebral blood flow (rCBF) was measured using 3D pseudo-continuous arterial spin labelling and sampled in native space using participant-specific hippocampus/subfield masks (CA1, subiculum, CA4/dentate gyrus). Twenty-one healthy controls (HC) were scanned using the same acquisition sequence, but without administration of diazepam or placebo. Mixed-design ANCOVAs and linear mixed-effects models were used to examine the effects of group (CHR-P placebo/diazepam vs. HC) and condition (CHR-P diazepam vs. placebo) on rCBF in the hippocampus as a whole and by subfield. Results Under the placebo condition, CHR-P individuals (mean[±SD] age: 24.1[±4.8] years, 15F) showed significantly elevated rCBF compared to HC (mean[±SD] age: 26.5[±5.1] years, 11F) in the hippocampus ( F (1,36)=8.2, p FDR =0.004) and across its subfields (all p FDR <0.001). Following diazepam, rCBF in the hippocampus (and subfields, all p FDR <0.001) was significantly reduced ( t (69)=-5.1, p FDR <0.001) and normalised to HC levels ( F (1,41)=0.3, p FDR =0.225). Conclusions Diazepam can normalise hippocampal hyperperfusion in CHR-P individuals, consistent with evidence implicating medial temporal GABAergic dysfunction in the pathophysiology of psychosis.

Year:

2024

Year:

2023

Collaborators (21)

James Stone

University of Sussex

UNITED KINGDOM
View details

Nicholas R Livingston

King's College London

UNITED KINGDOM
View details

Paolo Fusar-Poli

Associate Professor

King’s College London

UNITED KINGDOM
View details

David Taylor

King’s College London

UNITED KINGDOM
View details

Amelia Jewell

South London and Maudsley NHS Foundation Trust

UNITED KINGDOM
View details

Fernando Zelaya

King’s College London

UNITED KINGDOM
View details

Anthony A Grace

University of Pittsburgh

UNITED STATES
View details

Gabriel Devenyi

Affilate

McGill University

CANADA
View details

Tom Spencer

King’s College London

UNITED KINGDOM
View details

Amanda Stefanie Kiemes

King’s College London

UNITED KINGDOM
View details

James MacCabe

Professor

King’s College London

UNITED KINGDOM
View details

Philip McGuire

King’s College London

UNITED KINGDOM
View details

Andrea Ilario De Micheli

King’s College London

UNITED KINGDOM
View details

Gemma Modinos

Professor of Neuroscience & Mental Health

King’s College London

UNITED KINGDOM
View details

David Lythgoe

King’s College London

UNITED KINGDOM
View details

Steve Williams

King’s College London

UNITED KINGDOM
View details

Eromona Whiskey

South London and Maudsley NHS Foundation Trust

UNITED KINGDOM
View details

Richard Emsley

King’s College London

UNITED KINGDOM
View details

Luke Jelen

King’s College London

UNITED KINGDOM
View details

Alice Egerton

Reader in Neuropsychopharmacology

King’s College London

UNITED KINGDOM
View details

Paulina Lukow

University College London

UNITED KINGDOM
View details